The therapeutic landscape of hemophilia, a rare inherited bleeding disorder, has rapidly evolved, introducing several novel modalities: extended half-life (EHL) coagulation factor concentrates, non-factor therapies, hemostasis-rebalancing agents, and gene therapy. These advances have improved clinical outcomes by reduc...
T. Szántó, Riitta Lassila· Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.